Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

News | ACC | March 20, 2018

Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns

March 20, 2018 — Febuxostat, a gout ...

Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.

News | ACC | March 20, 2018

Canakinumab Does Not Prevent Progression of Diabetes

March 20, 2018 — The anti-inflammatory...

Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery

News | ACC | March 20, 2018

Dabigatran Reduces Major Cardiovascular Complications in Myocardial Injury After Noncardiac Surgery

March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart...

Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger

News | ACC | March 20, 2018

Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a...

Ticagrelor Has Comparable Safety to Clopidogrel after Heart Attack

Image from presentation, "Ticagrelor Versus Clopidogrel After Thrombolytic Therapy in Patients With St-Elevation Myocardial Infarction: A Randomized Clinical Trial," Berwanger

News | ACC | March 20, 2018

Ticagrelor Has Comparable Safety to Clopidogrel After Heart Attack

March 20, 2018 — Among people younger than 75 years who were given clot busters to treat a heart attack, taking the...

Reducing Co-Payments Improves Patient and Physician Adherence to Guideline-Recommended Treatment Post-Heart Attack, late-breaking trial at ACC.18.

Image from presentation, "Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study," Wang

News | ACC | March 20, 2018

Reducing Co-Payments Improves Patient, Physician Adherence to Guideline-Recommended Treatment Post-Heart Attack

March 20, 2018 — When patients who had a heart attack were given vouchers to cover their co-payments for...

Personalized Approach to Selecting Antiplatelet Drugs Improves Outcomes

Image from presentation, "The PHARMCLO Study," Diego Ardissino, M.D., F.A.C.C.

News | ACC | March 20, 2018

Personalized Approach to Selecting Antiplatelet Drugs Improves Outcomes

March 20, 2018 — Patients with acute coronary syndrome experienced a substantially lower rate of heart attack,...

News | ACC | March 20, 2018

Low-Dose ‘Triple Pill’ Lowers Blood Pressure More Than Usual Care

March 20, 2018 — A pill combining low doses of three...

Managing Blood Pressure in Barbershops Yields Substantial Improvements

Image from presentation, "A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops," Victor et al

News | ACC | March 20, 2018

Managing Blood Pressure in Barbershops Yields Substantial Improvements

March 20, 2018 — African-American men who received medical intervention aimed at controlling their...

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association. #ACC18

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association.

News | Antiplatelet and Anticoagulation Therapies | March 19, 2018

Heart Attack Risk Increases With Six-Month Dual Antiplatelet Therapy

March 19, 2018 — The combined rate of death from any cause, heart attack or stroke within 18 months was not...